Effect of formoterol fumarate treatment on exercise-induced bronchoconstriction in children

Authors: Pearlman, David; Milgrom, Henry; Till, Denise; Ziehmer, Barbara

Source: Annals of Allergy, Asthma and Immunology, Volume 97, Number 3, September 2006 , pp. 382-388(7)

Publisher: American College of Allergy, Asthma, & Immunology

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Background: Exercise-induced bronchoconstriction (EIB) is common, particularly in children.

Objectives: To compare the protective effect of single doses of formoterol fumarate via Aerolizer with placebo and albuterol in children with EIB.

Methods: In this randomized, double-blind, double-dummy, crossover trial, 23 children (aged 4-11 years) received formoterol, 12 or 24 μg; albuterol, 180 μg; or placebo at 4 separate visits. Protection against EIB was evaluated as the maximum percentage decrease in forced expiratory volume in 1 second (FEV1) from the preexercise value after exercise challenge tests (6-minute treadmill) conducted 15 minutes and 4, 8, and 12 hours after administration of the dose.

Results: The maximum percentage decrease in FEV1 after the 4-hour exercise test (primary efficacy variable) was significantly less for formoterol, 12 and 24 μg, vs placebo (P < .001 for both) or albuterol (P = .016 and .010, respectively); albuterol was not significantly different from placebo. Formoterol, 12 and 24 μg, differed from placebo at 8 hours (P = .002 and .001, respectively), with a smaller difference between albuterol and placebo (P = .045). Rescue medication use and a high dropout rate may have biased treatment differences at later time points. Protection against EIB (<20% maximum decrease in FEV1) across all time points was observed for 17 (77%) of 22 and 17 (74%) of 23 children with formoterol, 12 and 24 μg, respectively, compared with 8 (35%) of 23 with albuterol and 6 (27%) of 22 with placebo.

Conclusions: Single doses of formoterol, 12 or 24 μg, are effective in protecting against EIB in children, affording a statistically significantly greater protective effect than placebo or albuterol.

Document Type: Original article

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$28.00 plus tax      Refund Policy

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A